Empagliflozin in combination therapy for treating type 2 diabetes

  • Technology appraisal guidance
  • TA336
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence:

  • Shyangdan D, Jacob R, Connock M et al. Empagliflozin combination therapy for treating type 2 diabetes:A Single Technology Appraisal. July 2014

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Companies were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Companies, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Company:

  • Boehringer Ingelheim

Professional or specialist and patient or carer groups:

  • Association of British Clinical Diabetologists

  • Black and Ethnic Minority Diabetes Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • AstraZeneca

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Janssen

  • Merck Sharp and Dohme

  • Novo Nordisk

  • National Institute for Health Research Health Technology Assessment Programme

  • Warwick Evidence

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on empagliflozin by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Peter Winocour, Consultant Diabetologist and Clinical Director, nominated by Association of British Clinical Diabetologists and Royal College of Physicians – clinical specialist

  • Dr T Sathyapalan, Reader and Honorary Consultant Diabetologist, nominated by Association of British Clinical Diabetologists and Royal College of Physicians – clinical specialist

  • Aderonki Kuti, Chief Executive Officer, nominated by Black Ethnic Minority Diabetes Association

Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Boehringer Ingelheim

ISBN: 978‑1‑4731‑1094‑6